Patents by Inventor Felix Kopp

Felix Kopp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small molecule BAX inhibitors and uses thereof
    Patent number: 11938128
    Abstract: Compounds, compositions and method of using these compounds are disclosed for treating a disease or disorder in which it is desirable to inhibit BAX, such as a cardiovascular disease or disorder.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: March 26, 2024
    Assignees: Albert Einstein College of Medicine, The University of Manitoba
    Inventors: Evripidis Gavathiotis, Richard N. Kitsis, Thomas P. Garner, Dulguun Amgalan, Lorrie Kirshenbaum, Felix Kopp
  • PXR agonists and uses thereof for gut barrier dysfunction treatment and prevention
    Patent number: 11724998
    Abstract: Small molecule agonists of the pregnane X receptor (PXR), compositions and methods are disclosed for treating or preventing gut barrier dysfunction, an illness associated with gut barrier dysfunction, toxic or inflammatory injury to intestines, or leaky intestinal (gut) syndrome in a subject.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: August 15, 2023
    Assignees: Albert Einstein College of Medicine, Drexel University, Palacky University Olomouc
    Inventors: Sridhar Mani, Felix Kopp, Zdenek Dvorak, Sandhya Kortagere, Chamini Karunaratne
  • BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY
    Publication number: 20220313665
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Application
    Filed: June 7, 2022
    Publication date: October 6, 2022
    Applicant: Albert Einstein College of Medicine
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich Steidl
  • BAX activators and uses thereof in cancer therapy
    Patent number: 11382898
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 12, 2022
    Assignee: Albert Einstein College of Medicine
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich G. Steidl
  • BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY
    Publication number: 20200093802
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Application
    Filed: May 24, 2018
    Publication date: March 26, 2020
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich G. Steidl
  • SMALL MOLECULE BAX INHIBITORS AND USES THEREOF
    Publication number: 20200009132
    Abstract: Compounds, compositions and method of using these compounds are disclosed for treating a disease or disorder in which it is desirable to inhibit BAX, such as a cardiovascular disease or disorder.
    Type: Application
    Filed: March 9, 2018
    Publication date: January 9, 2020
    Inventors: Evripidis Gavathiotis, Richard N. Kitsis, Thomas Peter Garner, Dulguun Amgalan, Lorrie Kirshenbaum, Felix Kopp
  • PXR AGONISTS AND USES THEREOF FOR GUT BARRIER DYSFUNCTION TREATMENT AND PREVENTION
    Publication number: 20190367475
    Abstract: Small molecule agonists of the pregnane X receptor (PXR), compositions and methods are disclosed for treating or preventing gut barrier dysfunction, an illness associated with gut barrier dysfunction, toxic or inflammatory injury to intestines, or leaky intestinal (gut) syndrome in a subject.
    Type: Application
    Filed: January 18, 2018
    Publication date: December 5, 2019
    Inventors: Sridhar Mani, Felix Kopp, Zdenek Dvorak, Sandhya Kortagere, Chamini Karunaratne
  • Solutions of anhydrous lanthanide salts and its preparation
    Patent number: 8470982
    Abstract: The present invention relates to anhydrous solutions of MX3-Z LiA in a solvent, wherein M is a lanthanide including lanthanum, or yttrium or indium; z>0; and X and A are independently or both monovalent anions, preferably Cl, Br or I. The solution is readily prepared by dissolving or suspending MX3 or its hydrate and z equiv LiA in water or hydrophilic solvents, or mixtures thereof, removing the solvent under vacuum and dissolving the resulting powder in another solvent. The solution of MX3-Z LiA can advantageously be used e.g. in addition reactions of Grignard reagents to ketones and imines. Even the catalytic use of MX3-Z LiA is possible.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: June 25, 2013
    Assignee: Ludwig-Maximilians-Universitaet
    Inventors: Paul Knochel, Arkady Krasovskiy, Felix Kopp
  • Solutions of anhydrous lanthanide salts and its preparation
    Publication number: 20090326235
    Abstract: The present invention relates to anhydrous solutions of MX3-Z LiA in a solvent, wherein M is a lanthanide including lanthanum, or yttrium or indium; z>0; and X and A are independently or both monovalent anions, preferably Cl, Br or I. The solution is readily prepared by dissolving or suspending MX3 or its hydrate and z equiv LiA in water or hydrophilic solvents, or mixtures thereof, removing the solvent under vacuum and dissolving the resulting powder in another solvent. The solution of MX3-Z LiA can advantageously be used e.g. in addition reactions of Grignard reagents to ketones and imines. Even the catalytic use of MX3-Z LiA is possible.
    Type: Application
    Filed: September 1, 2006
    Publication date: December 31, 2009
    Inventors: Paul Knochel, Arkady Krasovskiy, Felix Kopp